OneMedPlace introduces a new series, “The Briefing Room”, capturing the most important developments in microcap life sciences indexes. This week, we focus on three interesting developments in oncology, and a special bonus!
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.